This study aims to (1) systematically evaluate the efficacy of contemporary neoadjuvant regimens in HER2-positive IMPC versus conventional carcinomas, (2) characterize distinct molecular features through bioinformatics analysis of gene expression profiles, and (3) elucidate differences in the tumor immune microenvironment through comparative assessment of pretreatment specimens. This evidence concerns the gene ERBB2 and neoplasm.